Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-2.53Last Year’s EPS
-4.4Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -17.43%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call highlights significant progress in the development and regulatory approval process of SER-155, with positive feedback from the medical community and improved financial performance. However, challenges in securing partnerships and navigating the biotech financing environment pose potential risks. Overall, the positive developments outweigh the challenges.Company Guidance
During the Seres Therapeutics First Quarter 2025 Earnings Conference Call, the company emphasized significant progress with SER-155, particularly in advancing it to the next clinical study phase. The Phase 1b study demonstrated a 77% relative risk reduction in bloodstream infections in allo-HSCT patients, with a favorable safety profile. The upcoming Phase 2 study, anticipated to include multiple European sites, aims to enroll 248 participants and incorporate an adaptive design with an interim analysis expected within 12 months of initiation. Financially, Seres reported a net income of $32.7 million for Q1 2025, largely due to a $50 million installment payment from Nestle, with cash and equivalents totaling $58.8 million as of March 31, 2025. The company expects to fund operations into Q1 2026, contingent on a second installment from Nestle and potential partnerships to support SER-155's development.Progress in Advancing SER-155
Significant progress is being made advancing SER-155 into the next stage of development in allo-HSCT, with a 77% relative risk reduction in bloodstream infections observed in Phase 1b study.
Encouragement from Medical Community
Positive feedback received from the European Society for Blood and Marrow Transplantation Conference, highlighting the medical community's support and interest in SER-155.
Financial Performance and Cost Management
Reported net income from continuing operations of $32.7 million in Q1 2025, compared to a net loss of $32.9 million in Q1 2024. R&D expenses reduced to $11.8 million from $19.5 million, and G&A expenses decreased to $11.9 million from $14.9 million.
Regulatory and Strategic Progress
Constructive interactions with FDA, incorporating feedback into Phase 2 study design for SER-155, aiming for a time and capital-efficient path to clinical data.
---
MCRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MCRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 07, 2025 | $8.55 | $8.29 | -3.04% |
| Mar 13, 2025 | $13.86 | $12.77 | -7.86% |
| Nov 13, 2024 | $13.28 | $11.80 | -11.14% |
| Aug 13, 2024 | $17.80 | $16.56 | -6.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Seres Therapeutics (MCRB) report earnings?
Seres Therapeutics (MCRB) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Seres Therapeutics (MCRB) earnings time?
Seres Therapeutics (MCRB) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCRB EPS forecast?
MCRB EPS forecast for the fiscal quarter 2025 (Q2) is -2.53.
---